MicroRNAs (miRNA) are small non-coding RNAs (∼ 22 nt in length) that are known as
potent master regulators of eukaryotic gene expression. miRNAs have been shown to play a …

Simple Summary The bone marrow (BM) microenvironment plays a crucial role in
pathogenesis of multiple myeloma (MM), and delineation of the intracellular signaling …

Purpose: Histone deacetylase (HDAC) inhibition improves the efficacy of proteasome
inhibition for multiple myeloma but adds substantial toxicity. Preclinical models suggest that …

Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the
side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and …

Background Histone deacetylase (HDAC) inhibitors are an important new class of
therapeutics for treating multiple myeloma. Ricolinostat (ACY-1215) is the first oral selective …

Anti-CD38 monoclonal antibody (MoAb) treatments including daratumumab (DARA) are
effective therapies for both newly diagnosed and relapsed multiple myeloma (MM). In this …

Epigenetic abnormalities are common in hematologic malignancies, including multiple
myeloma, and their effects can be efficiently counteracted by a class of tumor suppressor …

It is now well recognized that mutations, deregulated expression, and aberrant recruitment of
epigenetic readers, writers, and erasers are fundamentally important processes in the onset …

Multiple myeloma (MM) is a tumor of antibody producing plasmablasts/plasma cells that
resides within the bone marrow (BM). In addition to the well-established role of genetic …

Histone deacetylases (HDACs) are master regulators of chromatin remodeling, acting as
epigenetic regulators of gene expression. In the last decade, inhibition of HDACs has …